RxDoctor Payments DataLook up a doctor →

Paban Saha, MD

Clinical Cardiac Electrophysiology · Saint Louis, MONPI 1275698144

Payments from drug & device makers

$92,136in general payments, 2019–2025

Across 667 payments — averaging $138.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$46K
  • Abbott$33K
  • Biosense Webster, Inc.$7K
  • Medtronic$2K
  • Boston Scientific$2K
  • Medical Device Business Services, Inc.$1K
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$3,73319%
  • Travel & lodging$3,12316%
  • Food & beverage$12,80465%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,136 in reported general payments places this provider in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$527,559
Medicare patients
1,240
Services billed
4,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban444$426,548
XareltoRivaroxaban136$151,577
EntrestoSacubitril/Valsartan22$32,373
MultaqDronedarone Hcl12$16,549
Metoprolol Succinate592$9,070
Dofetilide12$6,405
Dabigatran EtexilateDabigatran Etexilate Mesylate13$4,160
SotalolSotalol Hcl166$2,990
Amiodarone Hcl140$1,921
Midodrine Hcl12$1,098
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$980
ClopidogrelClopidogrel Bisulfate72$903
Warfarin Sodium113$853
Lisinopril81$685
Carvedilol67$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$426,548444 claims
NovartisEntresto$12$32,37322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →